Evidence map›Paper›PMID 34234128›Full record

ArticleNPJ Parkinson's disease2021

TOMM40 '523' poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson's disease.

Megan C Bakeberg, Anastazja M Gorecki, Abigail L Pfaff, Madison E Hoes, Sulev Kõks, P Anthony Akkari, Frank L Mastaglia, Ryan S Anderton

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Megan C BakebergPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia. megan.bakeberg@research.uwa.edu.au.ORCID http://orcid.org/0000-0002-4452-6827
Anastazja M GoreckiPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia.
Abigail L PfaffPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia.ORCID http://orcid.org/0000-0002-2231-9800
Madison E HoesPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia.ORCID http://orcid.org/0000-0001-5062-3490
Sulev KõksPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia.ORCID http://orcid.org/0000-0001-6087-6643
P Anthony AkkariPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia.
Frank L MastagliaPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia.
Ryan S AndertonPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia.ORCID http://orcid.org/0000-0003-0568-9794

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The translocase of outer mitochondrial membrane 40 (TOMM40) '523' polymorphism has previously been associated with age of Alzheimer's disease onset and cognitive functioning in non-pathological ageing, but has not been explored as a candidate risk marker for cognitive decline in Parkinson's disease (PD). Therefore, this longitudinal study investigated the role of the '523' variant in cognitive decline in a patient cohort from the Parkinson's Progression Markers Initiative. As such, a group of 368 people with PD were assessed annually for cognitive performance using multiple neuropsychological protocols, and were genotyped for the TOMM40 '523' variant using whole-genome sequencing data. Covariate-adjusted generalised linear mixed models were utilised to examine the relationship between TOMM40 '523' allele lengths and cognitive scores, while taking into account the APOE ε genotype. Cognitive scores declined over the 5-year study period and were lower in males than in females. When accounting for APOE ε4, the TOMM40 '523' variant was not robustly associated with overall cognitive performance. However, in APOE ε3/ε3 carriers, who accounted for ~60% of the whole cohort, carriage of shorter '523' alleles was associated with more severe cognitive decline in both sexes, while carriage of the longer alleles in females were associated with better preservation of global cognition and a number of cognitive sub-domains, and with a delay in progression to dementia. The findings indicate that when taken in conjunction with the APOE genotype, TOMM40 '523' allele length is a significant independent determinant and marker for the trajectory of cognitive decline and risk of dementia in PD.

Identifiers

PMID34234128
PMCPMC8263775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.